Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above water this year.
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency…
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
24/7 Wall St. is taking a look at the bottom line for companies in the S&P 500 going into 2016, and we have chosen some of the least expensive stocks for the…
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
New data suggests that the stock market's performance in 2015 was bolstered or supported by the largest S&P 500 companies buying back their own stock.
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Over the past 10 years the single, most innovative company in the world has been Apple, according to the Boston Consulting Group.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Here are 10 stocks that could outperform the index funds from now to early February.
